Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Zentek ( (TSE:ZEN) ) is now available.
Zentek Ltd. has successfully completed the first in vivo tests of its lead candidate countermeasure for seasonal influenza (H1N1) using multivalent aptamer technology. The testing, part of the Innovative Solutions Canada Testing Stream, showed promising results, with treated animals exhibiting improved clinical scores and higher survival rates compared to the control group. This development, supported by a $1.1 million award from the Government of Canada, marks a significant step in Zentek’s efforts to address both seasonal and potentially pandemic influenza strains, positioning the company as a key player in the advanced medical technologies sector.
The most recent analyst rating on (TSE:ZEN) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on Zentek stock, see the TSE:ZEN Stock Forecast page.
Spark’s Take on TSE:ZEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:ZEN is a Neutral.
Zentek’s overall stock score is primarily impacted by its financial performance, which is challenged by negative profitability and cash flow issues. Technical analysis provides some short-term positive signals, but longer-term trends remain bearish. Valuation metrics are weak due to the company’s lack of profitability and absence of dividends. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on TSE:ZEN stock, click here.
More about Zentek
Zentek Ltd. is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of novel products. The company aims to provide its commercial partners with a competitive advantage by enhancing the safety, efficiency, and environmental friendliness of their products. Zentek’s patented technology platform, ZenGUARD™, is designed to significantly improve the bacterial and viral filtration efficiency of surgical masks and HVAC filters. The company operates a ZenGUARD™ production facility in Guelph, Ontario.
Average Trading Volume: 53,796
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$135.1M
See more data about ZEN stock on TipRanks’ Stock Analysis page.